# US 2025/0154191 A1 · Oligonucleotide production method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154191 A1
- Document ID: US20250154191A1
- Status: Published application
- Kind: A1
- Application number: 18/719,965
- Filed: 2022-12-16
- Published: 2025-05-15
- Earliest claimed: 2021-12-17
- Assignees: Liid Pharmaceuticals, Inc.
- Applicants: Liid Pharmaceuticals, Inc.
- Inventors: Yoshiyuki Hari; Yasufumi Fuchi; Yuta Ito; Kazuki Yamamoto
- Web page: https://patentgrep.com/patent/US20250154191A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C07H 1/00: Processes for the preparation of sugar derivatives
- C07H 19/067: with ribosyl as the saccharide radical
- C07H 19/073: with 2-deoxyribosyl as the saccharide radical
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

As a solid phase synthesis method of an oligonucleotide that enables cleavage of a synthesized oligonucleotide even under mild conditions, a solid phase synthesis method of an oligonucleotide, including a step of carrying a nucleotide derivative represented by the formula (I): wherein each symbol is as described in the specification, on a solid phase support via a universal linker, and the like are disclosed.

## Claims

### Claim 1

A solid phase synthesis method of an oligonucleotide, comprising a step of subjecting an oligonucleotide having, at the 3′-terminus of an oligonucleotide sequence thereof, a nucleotide derivative represented by the formula (II):
wherein * is a bonding position to the universal linker;
** is a bonding position to the nucleotide or oligonucleotide;
RZ is O or S;
X is methoxy, ethoxy, isopropoxy, isobutoxy, neopentyloxy phenyl-oxy, or methyl;
R1 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkenyloxy group, or an optionally substituted alkynyloxy group;
R2 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkenyloxy group, or an optionally substituted alkynyloxy group;
R3 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group, or an optionally substituted alkylthio group, or
R2 and R3 are bonded to each other to form a group represented by the following formula (shown in the order of —R2—R3—):
—O—C(Ra)2—, —O—C(Rb)2—C(Rc)2—, —O—C(Rd)2—O—, —N(Re)—C(Rf)2—, —N(Rg)—CO—,—S—C(Rh)2—, or —C(Ri)2—C(Rj)2—
in the above-mentioned formulas, Ra to Rj are each independently a hydrogen atom or an optionally substituted alkyl group; and
Base is an optionally modified nucleobase,
which oligonucleotide is carried on a solid phase support via a universal linker and synthesized by a nucleotide elongation reaction in a solid phase synthesis method of an oligonucleotide,
to a reaction for cleaving the oligonucleotide from the solid phase support and the universal linker.

### Claim 2

A solid phase synthesis method of an oligonucleotide, comprising
(1) a step of carrying a nucleotide derivative represented by the formula (I):
wherein X is methoxy, ethoxy, isopropoxy, isobutoxy, neopentyloxy, phenyl-oxy, or methyl;
Y is a hydrogen atom or a hydroxy-protecting group;
Z1 and Z2 are each independently an optionally substituted alkyl group;
R1 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkenyloxy group, or an optionally substituted alkynyloxy group;
R2 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkenyloxy group, or an optionally substituted alkynyloxy group;
R3 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group, or an optionally substituted alkylthio group, or
R2 and R3 are bonded to each other to form a group represented by the following formula (shown in the order of -R2-R3-):
—O—C(Ra)2—, —O—C(Rb)2—C(Rc)2—, —O—C(Rd)2—O—, —N(Re)—C(Rf)2—, —N(Rg)—CO—, —S—C(Rh)2—, or —C(Ri)2—C(Rj)2—
in the above-mentioned formulas, Ra to Rj are each independently a hydrogen atom or an optionally substituted alkyl group; and
Base is an optionally modified nucleobase,
on a solid phase support via a universal linker,
(2) a step of sequentially condensing nucleic acid monomers according to the desired oligonucleotide sequence to elongate the nucleotide (one or two or more nucleotide derivatives represented by the above-mentioned formula (I) may also be used as the nucleic acid monomers),
(3) a step of subjecting the obtained oligonucleotide having the desired sequence to a reaction for cleaving from the solid phase support and the universal linker.

### Claim 3 (depends on 1)

The solid phase synthesis method of an oligonucleotide according to claim 1, wherein the reaction for cleaving from the solid phase support and the universal linker is performed by contacting the solid phase support, on which the oligonucleotide is carried via a universal linker, with
1) concentrated aqueous ammonia at room temperature to under warming,
2) a mixed solution of concentrated alkylamine aqueous solution/concentrated aqueous ammonia at room temperature to under warming,
3) an alcohol solution of potassium carbonate at room temperature to under warming, or
4) a mixed solution of alkylamine/water or alkylamine/water/alcohol at room temperature to under warming.

### Claim 4 (depends on 3)

The solid phase synthesis method of an oligonucleotide according to claim 3, wherein the reaction for cleaving from the solid phase support is performed by contacting the solid phase support, on which the oligonucleotide is carried via a universal linker, with
1) 28% aqueous ammonia at room temperature,
2) a 1:1 mixed solution of 40% methylamine aqueous solution/28% aqueous ammonia (AMA solution) at room temperature,
3) a methanol solution of 50 mM potassium carbonate at room temperature, or
4) a mixed solution of t-butylamine/water or t-butylamine/water/methanol under warming.

### Claim 5

A nucleotide derivative represented by the formula (Ia):
wherein Xa is isobutoxy or neopentyloxy;
Y is a hydrogen atom or a hydroxy-protecting group;
Z1 and Z2 are each independently an optionally substituted alkyl group, or
R2 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkenyloxy group, or an optionally substituted alkynyloxy group;
R2 is a hydrogen atom, a halogen atom, an optionally protected hydroxy group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted alkenyloxy group, or an optionally substituted alkynyloxy group;
R3 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group, or an optionally substituted alkylthio group, or R2 and R3 are bonded to each other to form a group represented by the following formula (shown in the order of —R2—R3—):
—O—C(Ra)2—, —O—C(Rb)2—C(Rc)2—, —O—C(Rd)2—O—, —N(Re)—C(Rf)2—, —N(Rg)—CO—,—S—C(Rh)2—, or —C(Ri)2—C(Rj)2—
in the above-mentioned formulas, Ra to Rj are each independently a hydrogen atom or an optionally substituted alkyl group; and
Base is an optionally modified nucleobase.

### Claim 6

Use of a 1,2-diol derivative represented by the formula (III):
Y1—O—C(X1)(X2)C(X3)(X4)—O—Y2 (III)
wherein X1-X4 are each a hydrogen atom; and
Y1 and Y2 are each a hydrogen atom or a hydroxy-protecting group, as a universal linker for oligonucleotide solid phase synthesis.

### Claim 7 (depends on 1)

The solid phase synthesis method of an oligonucleotide according to claim 1, wherein X is isopropoxy or neopentyloxy.

### Claim 8 (depends on 3)

The solid phase synthesis method of an oligonucleotide according to claim 3, wherein X is isopropoxy or neopentyloxy.

### Claim 9 (depends on 3)

The solid phase synthesis method of an oligonucleotide according to claim 3, wherein Z1 and Z2 are each isopropyl.
